Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-9.80 Insider Own11.31% Shs Outstand4.16M Perf Week16.54%
Market Cap50.34M Forward P/E- EPS next Y-8.09 Insider Trans-31.45% Shs Float3.60M Perf Month15.67%
Income-36.12M PEG- EPS next Q-2.05 Inst Own76.61% Short Float9.33% Perf Quarter4.64%
Sales57.53M P/S0.88 EPS this Y52.03% Inst Trans-66.76% Short Ratio2.55 Perf Half Y10.52%
Book/sh5.38 P/B2.31 EPS next Y-5.62% ROA-14.82% Short Interest0.34M Perf Year-44.44%
Cash/sh33.93 P/C0.37 EPS next 5Y- ROE-74.56% 52W Range8.25 - 27.02 Perf YTD13.24%
Dividend Est.- P/FCF- EPS past 5Y7.97% ROI-80.95% 52W High-54.10% Beta1.72
Dividend TTM- Quick Ratio4.82 Sales past 5Y101.03% Gross Margin87.13% 52W Low50.30% ATR (14)0.86
Dividend Ex-Date- Current Ratio4.82 EPS Y/Y TTM71.72% Oper. Margin-75.48% RSI (14)58.55 Volatility6.47% 7.23%
Employees109 Debt/Eq0.83 Sales Y/Y TTM88.25% Profit Margin-62.78% Recom1.33 Target Price33.00
Option/ShortNo / Yes LT Debt/Eq0.20 EPS Q/Q125.11% Payout- Rel Volume0.30 Prev Close11.98
Sales Surprise229.33% EPS Surprise171.76% Sales Q/Q100.27% EarningsMay 13 BMO Avg Volume131.61K Price12.40
SMA2017.03% SMA503.96% SMA2002.72% Trades Volume38,953 Change3.51%
Date Action Analyst Rating Change Price Target Change
Apr-30-24Initiated Guggenheim Buy $19
Jun-17-22Initiated BMO Capital Markets Outperform $7
Jun-09-22Downgrade William Blair Outperform → Mkt Perform
Jul-27-20Resumed BTIG Research Buy $16
Apr-03-20Downgrade Goldman Buy → Neutral $24 → $7
Mar-05-20Initiated Stifel Buy $21
Feb-25-20Initiated William Blair Outperform
Aug-09-19Initiated BTIG Research Buy $22
Jul-16-19Initiated H.C. Wainwright Buy $21
Apr-22-19Initiated JP Morgan Overweight
May-17-24 07:00AM
May-13-24 11:53AM
08:15AM Loading…
May-08-24 08:15AM
May-07-24 04:30PM
May-03-24 09:33AM
May-01-24 07:05AM
Apr-16-24 04:15PM
Apr-11-24 09:55AM
Apr-02-24 09:55AM
Mar-27-24 11:53AM
08:10AM Loading…
Mar-20-24 04:30PM
Mar-19-24 07:00AM
Mar-14-24 08:15AM
Mar-06-24 08:45AM
Mar-01-24 06:30AM
Feb-29-24 04:01PM
Feb-27-24 04:25AM
Feb-20-24 07:00AM
Feb-14-24 07:00AM
Feb-13-24 07:00AM
Feb-12-24 07:00AM
07:00AM Loading…
Feb-09-24 07:00AM
Jan-09-24 07:00AM
Dec-13-23 08:20AM
Dec-04-23 07:00AM
Nov-30-23 07:00AM
Nov-28-23 07:00AM
Nov-14-23 08:55AM
Nov-13-23 07:05AM
Nov-10-23 07:00AM
Nov-09-23 07:00AM
Nov-07-23 07:54AM
Nov-01-23 07:00AM
Oct-26-23 07:30AM
Oct-23-23 07:00AM
Oct-12-23 08:00AM
Sep-27-23 07:00AM
Sep-12-23 07:00AM
Sep-06-23 07:00AM
Aug-31-23 07:00AM
Aug-22-23 07:32AM
Aug-18-23 09:35AM
Aug-15-23 07:04PM
Aug-06-23 08:03AM
Aug-04-23 08:35AM
Aug-01-23 05:00PM
Jul-27-23 07:30AM
Jul-13-23 01:03PM
Jun-22-23 07:00AM
Jun-05-23 07:00AM
May-31-23 07:15AM
May-25-23 07:00AM
May-24-23 08:00AM
May-19-23 07:00AM
May-12-23 05:06PM
May-09-23 08:15AM
May-08-23 04:30PM
May-02-23 07:00AM
Apr-20-23 08:00AM
Apr-19-23 04:22PM
Apr-17-23 07:34AM
Apr-13-23 07:00AM
Mar-27-23 07:00AM
Mar-09-23 08:15AM
Mar-07-23 06:33AM
Mar-02-23 07:00AM
Feb-24-23 07:00AM
Feb-22-23 07:00AM
Feb-14-23 07:00AM
Jan-20-23 08:13AM
Jan-09-23 07:30AM
Jan-06-23 07:00AM
Dec-10-22 10:00AM
Nov-11-22 10:04AM
Nov-10-22 05:00PM
Nov-08-22 08:25AM
Nov-04-22 07:19PM
Nov-03-22 09:40AM
Nov-02-22 07:00AM
Oct-26-22 07:00AM
Oct-25-22 06:40AM
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Amoroso MichaelPresident and CEOMay 02 '24Sale10.321,52615,74813,772May 03 06:29 PM
List AlanChief Medical OfficerMay 02 '24Sale10.322902,9934,488May 03 06:30 PM
Scimeca DarioGeneral Counsel and SecretaryMay 02 '24Sale10.322722,8075,680May 03 06:33 PM
SMITH J. JEFFERSONChief Research OfficerMay 02 '24Sale10.321541,58967,613May 03 06:32 PM
List AlanChief Medical OfficerApr 30 '24Sale10.032382,3863,796Apr 30 06:34 PM
SMITH J. JEFFERSONChief Research OfficerJan 23 '24Sale0.3728,00010,3601,987,269Jan 23 07:11 PM
Amoroso MichaelPresident and CEOJan 22 '24Sale0.36137,39049,460356,433Jan 23 07:17 PM
List AlanChief Medical OfficerJan 22 '24Sale0.3621,5267,74994,982Jan 23 07:13 PM
Scimeca DarioGeneral Counsel and SecretaryJan 22 '24Sale0.3621,2877,663151,028Jan 23 07:15 PM
Amoroso MichaelPresident and CEONov 03 '23Sale0.40125,02550,010227,103Nov 06 05:07 PM
Scimeca DarioGeneral Counsel and SecretaryNov 03 '23Sale0.4016,0236,409112,970Nov 06 05:09 PM
Scimeca DarioGeneral Counsel and SecretaryJun 08 '23Sale0.7513,36110,02168,473Jun 09 04:15 PM